Trial Profile
A randomized, open label study of the effect of MabThera [rituximab; Rituxan] on quality of life (QOL) and treatment response in patients with rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2010
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Disease-modifying antirheumatics; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Planned number of patients changed from 98 to 138 as reported by Roche record.
- 19 Jun 2008 New trial record.